Legend Biotech (NASDAQ: LEGN) surged 18.42% on Monday, significantly outperforming the S&P 500, which dipped 0.2%. The stock’s rally was driven by bullish updates from analysts at H.C. Wainwright and RBC Capital, both reiterating buy recommendations. RBC’s Leonid Timashev set a price target of $62 per share, citing excitement from Eli Lilly’s acquisition of Kelonia Therapeutics, which underscores the market’s interest in CAR-T therapies, a space where Legend is actively developing its pipeline.

The analysts’ optimism is bolstered by positive developments in Legend’s clinical trials, particularly the upcoming data release for its CD19/CD20 therapy. This innovative approach to cancer treatment positions Legend favorably within the biotech sector, especially as major players like Eli Lilly invest heavily in similar technologies.

For market professionals, Legend’s strong performance and promising pipeline make it a stock to monitor closely. The ongoing advancements in CAR-T therapies could not only enhance Legend’s valuation but also attract further interest from institutional investors.

Source: fool.com